المؤلفون: Nagar S; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania korzekwa@temple.edu swati.nagar@temple.edu., Parise R; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania., Korzekwa K; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania korzekwa@temple.edu swati.nagar@temple.edu.

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Sep 16; Vol. 52 (10), pp. 1060-1072. Date of Electronic Publication: 2024 Sep 16.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological* , Hepatocytes*/metabolism , Liver*/metabolism , Permeability* , Microsomes, Liver*/metabolism , Metabolic Clearance Rate*/physiology, Humans ; Animals ; Pharmaceutical Preparations/metabolism ; Pharmacokinetics ; Protein Binding/physiology

المؤلفون: Schulz Pauly JA; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Sande E; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Feng M; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Wang YT; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Stresser DM; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Kalvass JC; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois j.kalvass@abbvie.com.

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Sep 16; Vol. 52 (10), pp. 1048-1059. Date of Electronic Publication: 2024 Sep 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Hepatocytes*/metabolism , Metabolic Clearance Rate* , Liver*/metabolism, Humans ; Pharmaceutical Preparations/metabolism ; Proof of Concept Study ; Biological Transport/physiology ; Cells, Cultured ; Hepatobiliary Elimination/physiology ; Models, Biological ; Cytochrome P-450 Enzyme System/metabolism

المؤلفون: Poulin P; Consultant Patrick Poulin Inc., Québec City, Québec, Canada; School of Public Health, Université de Montréal, Montréal, Québec, Canada. Electronic address: patrick-poulin@videotron.ca.

المصدر: Journal of pharmaceutical sciences [J Pharm Sci] 2024 Aug; Vol. 113 (8), pp. 2641-2650. Date of Electronic Publication: 2024 May 24.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6017 (Electronic) Linking ISSN: 00223549 NLM ISO Abbreviation: J Pharm Sci Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological* , Liver*/metabolism , Protein Binding* , Metabolic Clearance Rate*, Humans ; Pharmaceutical Preparations/metabolism ; Hepatocytes/metabolism ; Kinetics ; Albumins/metabolism ; Microsomes, Liver/metabolism ; Pharmacokinetics

المؤلفون: Pang KS; Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada (K.S.P., W.I.L.) and Department of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands (G.J.M.) ks.pang@utoronto.ca., Lu WI; Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada (K.S.P., W.I.L.) and Department of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands (G.J.M.)., Mulder GJ; Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada (K.S.P., W.I.L.) and Department of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands (G.J.M.).

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Jul 16; Vol. 52 (8), pp. 919-931. Date of Electronic Publication: 2024 Jul 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological* , Liver*/metabolism , Metabolic Clearance Rate*/physiology, Humans ; Animals ; Pharmaceutical Preparations/metabolism ; Hepatobiliary Elimination/physiology ; Pharmacokinetics

المؤلفون: Kukla DA; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois., Belair DG; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois., Stresser DM; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois david.stresser@abbvie.com.

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Jul 16; Vol. 52 (8), pp. 797-812. Date of Electronic Publication: 2024 Jul 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Hepatocytes*/metabolism , Spheroids, Cellular*/metabolism , Metabolic Clearance Rate*, Humans ; Microsomes, Liver/metabolism ; Pharmaceutical Preparations/metabolism ; Models, Biological ; Cytochrome P-450 CYP3A/metabolism ; Cell Culture Techniques/methods ; Cells, Cultured

المؤلفون: Weiss M; Department of Pharmacology, Martin Luther University Halle-Wittenberg, Magdeburger Straße 20 (Saale), 06112, Halle, Germany. michael.weiss@medizin.uni-halle.de.

المصدر: Pharmaceutical research [Pharm Res] 2024 Jul; Vol. 41 (7), pp. 1391-1400. Date of Electronic Publication: 2024 Jul 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-904X (Electronic) Linking ISSN: 07248741 NLM ISO Abbreviation: Pharm Res Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological* , Pharmacokinetics* , Metabolic Clearance Rate*, Humans ; Pharmaceutical Preparations/metabolism ; Drug Interactions ; Tissue Distribution

المؤلفون: Preiss LC; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Georgi K; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Lauschke VM; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Petersson C; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.) carl.petersson@merckgroup.com.

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 May 16; Vol. 52 (6), pp. 539-547. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Coculture Techniques*/methods , Hepatocytes*/metabolism , Liver*/metabolism , Models, Biological* , Metabolic Clearance Rate* , Spheroids, Cellular*/metabolism, Humans ; Pharmaceutical Preparations/metabolism

المؤلفون: Zheng J; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Lu B; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Carr G; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Mwangi J; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Wang K; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Hao J; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Staiger KM; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Kozon N; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Murray BP; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Bashir M; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Gohdes MA; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Tse WC; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Schroeder S; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Graupe M; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Link JO; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Yoon J; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Chiu A; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Rowe W; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Smith BJ; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Subramanian R; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.) Raju.Subramanian@gilead.com.

المصدر: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2024 Sep 18; Vol. 391 (1), pp. 91-103. Date of Electronic Publication: 2024 Sep 18.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE

مواضيع طبية MeSH: Rats, Sprague-Dawley*, Animals ; Rats ; Humans ; Male ; Dogs ; Tissue Distribution ; Intestinal Elimination ; Quinolines/pharmacokinetics ; Metabolic Clearance Rate ; Isomerism

المؤلفون: Bauman JN; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.) jonathan.bauman@pfizer.com., Doran AC; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Gualtieri GM; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Hee B; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Strelevitz T; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Cerny MA; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Banfield C; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Plotka A; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Wang X; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Purohit VS; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Dowty ME; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.).

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Sep 16; Vol. 52 (10), pp. 1124-1136. Date of Electronic Publication: 2024 Sep 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Protein Kinase Inhibitors*/pharmacokinetics , Protein Kinase Inhibitors*/administration & dosage, Humans ; Male ; Adult ; Janus Kinase 3/antagonists & inhibitors ; Janus Kinase 3/metabolism ; Administration, Oral ; Young Adult ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/metabolism ; Metabolic Clearance Rate ; Middle Aged ; Biological Availability ; Half-Life ; Administration, Intravenous

المؤلفون: Benet LZ; Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA, USA. Electronic address: leslie.benet@ucsf.edu., Tiitto MV; Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA, USA., Sodhi JK; Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA, USA.

المصدر: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Sep; Vol. 373, pp. 564-567. Date of Electronic Publication: 2024 Jul 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

مواضيع طبية MeSH: Delayed-Action Preparations*/pharmacokinetics , Liver*/metabolism, Humans ; Metabolic Clearance Rate ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/metabolism ; Drug Delivery Systems ; Models, Biological ; Drug Development/methods